Burden of illness for super-refractory status epilepticus patients

被引:23
作者
Beg, Jamil M. [1 ]
Anderson, Thomas D. [1 ]
Francis, Kevin [2 ]
Meckley, Lisa M. [2 ]
Fitzhenry, David [2 ]
Foster, Todd [2 ]
Sukhtankar, Susheel [2 ]
Kanes, Stephen J. [1 ]
Moura, Lidia M. V. R. [3 ]
机构
[1] Sage Therapeut Inc, 215 First St, Cambridge, MA 02142 USA
[2] Trinity Partners, Waltham, MA USA
[3] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA
关键词
Epilepsy; Super-refractory status epilepticus; Cost; Resource utilization; Burden of illness; Hospitalization; CONVULSIVE STATUS EPILEPTICUS; ADMINISTRATIVE DATA; CASE-DEFINITION; ICD CODES; EPILEPSY; VALIDATION; MORTALITY; RECOMMENDATIONS; PREVALENCE; PREDICTORS;
D O I
10.1080/13696998.2016.1223680
中图分类号
F [经济];
学科分类号
02 ;
摘要
Objective: To provide an estimate of the annual number of super-refractory status epilepticus (SRSE) cases in the US and to evaluate utilization of hospital resources by these patients. Methods: The Premier Hospital Database was utilized to estimate the number of SRSE cases based on hospital discharges during 2012. Discharges were classified as SRSE cases based on an algorithm using seizure-related International Classification of Diseases-9 (ICD-9) codes, Intensive Care Unit (ICU) length of stay (LOS), and treatment protocols (e.g. benzodiazepines, anti-epileptic drugs (AEDs), and ventilator use). Secondary analyses were conducted using more restrictive algorithms for SRSE. Results: A total of 6,325 hospital discharges were classified as SRSE cases from a total of 5,300,000 hospital discharges. Applying a weighting based on hospital characteristics and 2012US demographics, this projected to an estimated 41,156 cases of SRSE in the US during 2012, an estimated incidence rate of similar to 13/100,000 annually for SRSE in the US. Secondary analyses using stricter SRSE algorithms resulted in estimated incidence rates of similar to 11/100,000 and 8/100,000 annually. The mean LOS for SRSE hospitalizations was 16.5 days (median =11; interquartile range [IQR]=6-20), and the mean ICU LOS was 9.3 days (median =6; IQR =3-12). The mean cost of an SRSE hospitalization was $51,247 (median = $33,294; 95% CI = $49,634-$52,861). Limitations: The analysis uses ICD-9 diagnostic codes and claims information, and there are inherent limitations in any methodology based on treatment protocol, which created challenges in distinguishing with complete accuracy between SRSE, RSE, and SE on the basis of care patterns in the database. Conclusion: SRSE is associated with high mortality and morbidity, which place a high burden on healthcare resources. Projections based upon the findings of this study suggest an estimated 25,821-41,959 cases of SRSE may occur in the US each year, but more in-depth studies are required.
引用
收藏
页码:45 / 53
页数:9
相关论文
共 50 条
  • [21] Refractory and super-refractory status epilepticus in adults: a 9-year cohort study
    Delaj, L.
    Novy, J.
    Ryvlin, P.
    Marchi, N. A.
    Rossetti, A. O.
    ACTA NEUROLOGICA SCANDINAVICA, 2017, 135 (01): : 92 - 99
  • [22] Ketogenic diet treatment for pediatric super-refractory status epilepticus
    Appavu, Brian
    Vanatta, Lisa
    Condie, John
    Kerrigan, John F.
    Jarrar, Randa
    SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2016, 41 : 62 - 65
  • [23] The risk of hypoglycemia and the ketogenic diet for super-refractory status epilepticus patients
    Brozova, Klara
    Broz, Jan
    BRAIN & DEVELOPMENT, 2019, 41 (08) : 740 - 740
  • [24] The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy
    Shorvon, Simon
    Ferlisi, Monica
    BRAIN, 2012, 135 : 2314 - 2328
  • [25] Vagus nerve stimulation in refractory and super-refractory status epilepticus - A systematic review
    Dibue-Adjei, Maxine
    Brigo, Francesco
    Yamamoto, Takamichi
    Vonck, Kristl
    Trinka, Eugen
    BRAIN STIMULATION, 2019, 12 (05) : 1101 - 1110
  • [26] Consensus Protocol the Treatment of super-Refractory Status Epilepticus
    Gomes, Daniel
    Pimentel, Jose
    Bentes, Carla
    Aguiar De Sousa, Diana
    Antunes, Ana Patricia
    Alvarez, Antonio
    Costa e Silva, Zelia
    ACTA MEDICA PORTUGUESA, 2018, 31 (10): : 598 - 605
  • [27] Management of super-refractory status epilepticus with isoflurane and hypothermia
    Zhumadilov, Agzam
    Gilman, Charles P.
    Viderman, Dmitriy
    FRONTIERS IN NEUROLOGY, 2015, 5
  • [28] Pharmacotherapy for Refractory and Super-Refractory Status Epilepticus in Adults
    Holtkamp, Martin
    DRUGS, 2018, 78 (03) : 307 - 326
  • [29] Stiripentol for the treatment of super-refractory status epilepticus with cross-sensitivity
    Uchida, Y.
    Terada, K.
    Madokoro, Y.
    Fujioka, T.
    Mizuno, M.
    Toyoda, T.
    Kato, D.
    Matsukawa, N.
    ACTA NEUROLOGICA SCANDINAVICA, 2018, 137 (04): : 432 - 437
  • [30] Treatment of Super-Refractory Status Epilepticus: A Review
    Ochoa, Juan G.
    Dougherty, Michelle
    Papanastassiou, Alex
    Gidal, Barry
    Mohamed, Ismail
    Vossler, David G.
    EPILEPSY CURRENTS, 2021, 21 (06) : 405 - 415